162 related articles for article (PubMed ID: 16230877)
1. Time as a variable with niacin extended-release/lovastatin vs. atorvastatin and simvastatin.
Bays HE; McGovern ME
Prev Cardiol; 2005; 8(4):226-33. PubMed ID: 16230877
[TBL] [Abstract][Full Text] [Related]
2. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
Bays HE; Dujovne CA; McGovern ME; White TE; Kashyap ML; Hutcheson AG; Crouse JR;
Am J Cardiol; 2003 Mar; 91(6):667-72. PubMed ID: 12633795
[TBL] [Abstract][Full Text] [Related]
3. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin.
Bays HE; McGovern ME
Prev Cardiol; 2003; 6(4):179-88. PubMed ID: 14605511
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.
Gentile S; Turco S; Guarino G; Sasso CF; Amodio M; Magliano P; Salvatore T; Corigliano G; Agrusta M; De Simone G; Gaeta I; Oliviero B; Torella R
Diabetes Obes Metab; 2000 Dec; 2(6):355-62. PubMed ID: 11225965
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of simvastatin and lovastatin/extended- release niacin to achieve LDL and HDL goal using NHANES data.
Armstrong EP; Zachry WM; Malone DC
J Manag Care Pharm; 2004; 10(3):251-8. PubMed ID: 15228376
[TBL] [Abstract][Full Text] [Related]
6. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins.
Andrews TC; Ballantyne CM; Hsia JA; Kramer JH
Am J Med; 2001 Aug; 111(3):185-91. PubMed ID: 11530028
[TBL] [Abstract][Full Text] [Related]
7. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.
Brown AS; Bakker-Arkema RG; Yellen L; Henley RW; Guthrie R; Campbell CF; Koren M; Woo W; McLain R; Black DM
J Am Coll Cardiol; 1998 Sep; 32(3):665-72. PubMed ID: 9741509
[TBL] [Abstract][Full Text] [Related]
8. Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy.
Toth PP; Thakker KM; Jiang P; Padley RJ
Vasc Health Risk Manag; 2012; 8():39-44. PubMed ID: 22323895
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
[TBL] [Abstract][Full Text] [Related]
11. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ
Am J Cardiol; 2004 Jan; 93(1):31-9. PubMed ID: 14697462
[TBL] [Abstract][Full Text] [Related]
12. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
Smith DG; McBurney CR
Pharmacoeconomics; 2003; 21 Suppl 1():13-23. PubMed ID: 12648031
[TBL] [Abstract][Full Text] [Related]
13. Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy.
Insull W; Toth PP; Superko HR; Thakkar RB; Krause S; Jiang P; Parreno RA; Padley RJ
Vasc Health Risk Manag; 2010 Nov; 6():1065-75. PubMed ID: 21191426
[TBL] [Abstract][Full Text] [Related]
14. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
[TBL] [Abstract][Full Text] [Related]
15. Managing dyslipidemia in the high-risk patient.
Stein EA
Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
[TBL] [Abstract][Full Text] [Related]
16. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification].
Li XP; Duan J; Zhao SP; Tan MY; Xu ZM; Zhang DQ
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(34):2399-403. PubMed ID: 17156651
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
[TBL] [Abstract][Full Text] [Related]
19. Randomized comparative study of the effects of treatment with once-daily, niacin extended-release/lovastatin and with simvastatin on lipid profile and fibrinolytic parameters in Taiwan.
Lin TH; Voon WC; Yen HW; Huang CH; Su HM; Lai WT; Sheu SH
Kaohsiung J Med Sci; 2006 Jun; 22(6):257-65. PubMed ID: 16793562
[TBL] [Abstract][Full Text] [Related]
20. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
Rader DJ; Davidson MH; Caplan RJ; Pears JS
Am J Cardiol; 2003 Mar; 91(5A):20C-23C; discussion 23C-24C. PubMed ID: 12646340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
